References
- Uckun F.M., Evans W.E., Forsyth C.J., Waddick K.G., T-Ahlgren L., Chelstrom L.M., Burkhardt A., Bolen J., Myers D.E. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 1995; 267: 886–891
- Myers D.E., Jun X., Waddick K.G., Forysth C., Chelstrom L.M., Gunther R.L., Turner N.E., Bolen J., Uckun F.M. Membrane-associated CD19-LYN complex is an endogenous p53-independent and bcl-2-independent regulator of apoptosis in human B-lineage lymphoma cells. Proc Nat'l Acad Sci USA. 1995; 92: 9575–9579
- Myers D.E., Sicheneder A., Clementson D., Dvorak N., Venkatachalam T., Rostovsev A., Chandan-Langlie M., Uckun F.M. Large scale manufacturing of B43(anti-CD19)-Genistein for clinical trials in leukemia and lymphoma. Leukemia and Lymphoma 1997, in press
- Gunther R., Chelstrom L.M., Wendorf H.R., Schneider E.A., Covalciuc K., Johnson B., Clementson D., Irvin J.D., Myers D.E., Uckun F.M. Toxicity profile of the investigational biotherapeutic agent, B43 (anti-CD 19)-pokeweed antiviral protein immunotoxin. Leukemia and Lymphoma 1996; 22: 61–70
- Waurzyniak B., Lisowski E., Wendorf H., Chelstrom L., Myers D.E., Irvin J., Ek O., Zeren T., Yanishevski Y., Langlic M., Evans W., Messinger Y., Gunther R., Uckun F.M. Pharmacokinetic features, toxicity and in vivo., anti-leukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. Clinical Cancer Research 1997; 3: 881–890
- Gerlowski L.E., Jain R.K. Physiologically based pharmacokinetic modeling: principles and applications. J. Pharm. Sci. 1983; 72: 1103–1126